Overview

The Combination Therapy With Ra-223 and Enzalutamide

Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
Phase:
Phase 2
Details
Lead Sponsor:
Taro Iguchi, MD, PHD
Collaborator:
Bayer Yakuhin, Ltd.